A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

← catalyst calendar

NCT02138734 · readout in 42 d

Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.

Phase

Phase 1/2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

369actual

Sites

108

Countries

India, South Africa, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2014-07-21

actual

When the study began enrolling

Primary completion

2026-09-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2039-03-04

estimated

The whole study's end, after follow-up

First posted

2014-05-15

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-31

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non-muscle Invasive Bladder Cancer

Interventions

Biological: BCG (50mg/instillation) + N-803 (400 μg/instillation)
Biological: BCG (50mg/instillation)

Primary outcomes

what the primary-completion date above is the date OF

Complete Response (CR) Rate

measured 6 Months

Disease Free Survival (DFS)

measured 13 Years and 3 Months

Publications

PMID 38953850 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed